The clinical trial of the future

The industry is approaching a new age of trials that are streamlined, connected and more engaged with the patient – but only if pharma can embrace the changes
On target?

Precision medicine is fundamentally changing how we treat patients, but is it too early to get excited about this burgeoning area?
International Clinical Researcher of the Year 2017: Entries are Open!

Invest in yourself and gain international recognition for your achievements. Entries for the International Clinical Researcher of the Year 2017 competition are now open.
Calling international marketers, senior marketers and marketing teams

There is still time to enter the PharmaTimes Marketer of the Year 2016 competition.

News

View all

GSK files for approval of subcutaneous lupus drug

GlaxoSmithKline has filed for approval of a subcutaneous formulation of its lupus drug Benlysta on both sides of the Atlantic.

26th September 2016

NICE clears Gilead’s pan-genotypic hep C drug Epclusa

The National Institute for Health and Care Excellence is endorsing Gilead's pan-genotypic hepatitis C drug Epclusa for routine NHS use in England and Wales.

26th September 2016

Latest SBRI comp offers £1.1m for GP innovations

NHS England investment fund SBRI Healthcare has launched its autumn competition offering entrepreneurs the opportunity for funding to drive forward their innovations within general practice.

26th September 2016

FDA approves the first Humira biosimilar

US regulators have issued a green light for the first biosimilar of AbbVie's biologic Humira, the world second best-selling drug.

26th September 2016

EU approves Allergan’s IBS drug

European regulators have issued a green light for Allergan's Truberzi, giving patients potential access to the first approved treatment for irritable bowel syndrome with diarrhoea (IBS-D).

23rd September 2016

Web Exclusives

View all

Making precision medicine work

Cancer Research UK's head of precision medicine on how the charity is preparing the NHS for this paradigm shift in treatment

Inclusion criteria

With new research showing that pharma senior teams are less diverse than comparable industries, companies could do more to instil a culture of inclusion

Now it's personal

Putting the right tools in patients' hands could personalise treatment and improve health across the board

Industry roundup – 21 July

Biobank banks genes of long-lived Sardinians; stem cell therapies face commercial challenges; VBI moves forward with Zika Vaccine

Magazine

View more from the latest edition

The clinical trial of the future

The industry is approaching a new age of trials that are streamlined, connected and more engaged with the patient – but only if pharma can embrace the changes

On target?

Precision medicine is fundamentally changing how we treat patients, but is it too early to get excited about this burgeoning area?

Pharma-sponsored medical education has always been about much more than just education, yet with greater transparency, changing learning styles and increased influence of expert patients, what does the future hold for pharma's wider interactions with healthcare professionals?